To prepare the oral self-microemulsifying drug delivery system (SMEDDS) of GBE50, balance solubility method was used to screen emulsifier and assistant emulsifier; a pseudo-tamary phase diagram was used to prepare microemulsion; and orthogonal design was used to optimize formulation. Self-microemulsifying efficiency, dissolution, stability and pharmacokinetics of the preparation were studied. As a result, GBE50-SMEDDS of IPM, Cremophor EL, 1,2-propanediol and GBE50 could be self emulsified to form stable microemulsion with particle diameter between 20 and 50 nm when emulsifying with water. Its self-microemulsifying efficiency and dissolution are quick with good stability and it has a higher bioavailability than market existing agents Xingling particles. GBE50-SMEDDS is stable and effective.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Locally Acting Budesonide-Loaded Solid Self-Microemulsifying Drug Delivery Systems (SMEDDS) for Distal Ulcerative Colitis.
Int J Nanomedicine
November 2024
Department of Anatomical Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
Background: Budesonide (BUD) is a BCS class II medication with poor water solubility and limited oral bioavailability. In this study, innovative solid self-microemulsifying drug delivery systems (BUD-SMEDDS) were developed for effective local management of distal ulcerative colitis (UC).
Methods: Based on solubility and emulsification tests, the components of the self-microemulsifying drug delivery system (SMEDDS) were Capryol™ 90, Tween 80, and Transcutol HP.
Self-microemulsifying drug delivery system-based gastroretentive in situ raft of pazopanib with enhanced solubility and bioavailability.
Arch Pharm (Weinheim)
January 2025
Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, India.
Pazopanib hydrochloride (PZH) is a Biopharmaceutics Classification System class II drug that faces challenges at the formulation forefront including low aqueous solubility (0.043 mg/mL) and poor oral bioavailability (14-39%). The present investigation aimed to develop a self-microemulsifying drug delivery system (SMEDDS) of PZH using a blend of Capryol® 90, Labrasol®, and propylene glycol to improve its solubility.
View Article and Find Full Text PDFSelf-Microemulsifying Drug Delivery System to Enhance Oral Bioavailability of Berberine Hydrochloride in Rats.
Pharmaceutics
August 2024
Department of Pharmaceutics, Jiangsu Agri-Animal Husbandry Vocational College, No. 8, Fenghuang East Road, Taizhou 225300, China.
Article Synopsis
- Berberine hydrochloride (BH) is a beneficial compound with low oral bioavailability, prompting researchers to create a new delivery system called BH-loaded self-microemulsifying drug delivery system (BH-SMEDDS) to improve its effectiveness.
- The optimal BH-SMEDDS formulation consisted of specific percentages of Capmul MCM, Kolliphor RH 40, and 1,2-propanediol, resulting in stable physicochemical properties and rapid self-emulsification.
- In tests, the new delivery system showed a significant increase in BH release and achieved 1.63 times higher oral bioavailability than standard BH tablets, indicating its potential for better clinical use.
Development of fexofenadine self-microemulsifying delivery systems: an efficient way to improve intestinal permeability.
Ther Deliv
September 2024
Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
The present study aimed to prepare and evaluate fexofenadine self-microemulsifying drug-delivery systems (SMEDDS) formulation and to determine and compare its intestinal permeability using single-pass intestinal perfusion (SPIP) technique. Fexofenadine-loaded SMEDDS were prepared and optimized. Droplet size, polydispersity index, zeta potential, drug release and intestinal permeability were evaluated.
View Article and Find Full Text PDFDevelopment of a self-microemulsifying drug delivery system to deliver delamanid via a pressurized metered dose inhaler for treatment of multi-drug resistant pulmonary tuberculosis.
Int J Pharm
April 2024
Drug Delivery System Excellence Center, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, Thailand. Electronic address:
Tuberculosis (TB) is a serious health issue that contributes to millions of deaths throughout the world and increases the threat of serious pulmonary infections in patients with respiratory illness. Delamanid is a novel drug approved in 2014 to deal with multi-drug resistant TB (MDR-TB). Despite its high efficiency in TB treatment, delamanid poses delivery challenges due to poor water solubility leading to inadequate absorption upon oral administration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!